keyword
MENU ▼
Read by QxMD icon Read
search

pharmaceutical trials

keyword
https://www.readbyqxmd.com/read/29232031/systematic-review-and-meta-analysis-of-reported-adverse-events-of-long-term-intranasal-oxytocin-treatment-for-autism-spectrum-disorder
#1
REVIEW
Qizheng Cai, Lei Feng, Kai Zhen Yap
Recent studies suggested oxytocin as a possible drug to treat social deficits caused by Autism Spectrum Disorder (ASD), but the safety of intranasal oxytocin in autistic patients is not established. The aim of this review was to characterise the side effect profile of long-term intranasal oxytocin in treatment of ASD compared to placebo. All randomised controlled trials of intranasal oxytocin in the treatment of ASD published before 1 January 2017 that reported safety data were identified from databases including Pubmed, Embase, Cochrane Library, and International Pharmaceutical Abstract...
December 12, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29231539/-effects-of-gao-s-neck-acupuncture-on-swallowing-function-and-quality-of-life-in-patients-with-post-stroke-pseudobulbar-palsy-a-randomized-controlled-trial
#2
Jiamei Chu, Xiaoping Liu, Feiyu Chen, Feifei Hong, Yehua Bao
OBJECTIVE: To observe the effects of GAO's neck acupuncture combined with swallowing rehabilitation on swallowing function and quality of life in patients with post-stroke pseudobulbar palsy. METHODS: One hundred patients were randomly assigned in to an observation group and a control group, 50 cases in each one. The patients in the control group were treated with basic pharmaceutical treatment, including neurotrophy medication and free radical scavenging medication as well as swallowing rehabilitation; the patients in the observation group, on the basis of those in the control group, were treated with GAO's neck acupuncture at Fengchi (GB 20), Yiming (EX-HN 14), Gongxue (Extra), Lianquan (CV 23), Wai Jinjin Yuye (Extra), Tunyan (Extra), Zhiqiang (Extra), Fayin (Extra), once a day, five times a week for continuous eight weeks...
July 12, 2017: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
https://www.readbyqxmd.com/read/29230567/cancer-nanomedicine-a-review-of-recent-success-in-drug-delivery
#3
REVIEW
Stephanie Tran, Peter-Joseph DeGiovanni, Brandon Piel, Prakash Rai
Cancer continues to be one of the most difficult global healthcare problems. Although there is a large library of drugs that can be used in cancer treatment, the problem is selectively killing all the cancer cells while reducing collateral toxicity to healthy cells. There are several biological barriers to effective drug delivery in cancer such as renal, hepatic, or immune clearance. Nanoparticles loaded with drugs can be designed to overcome these biological barriers to improve efficacy while reducing morbidity...
December 11, 2017: Clinical and Translational Medicine
https://www.readbyqxmd.com/read/29226873/modeling-prion-like-processing-of%C3%A2-tau%C3%A2-protein-in-alzheimer-s-disease-for%C3%A2-pharmaceutical-development
#4
Claude M Wischik, Björn O Schelter, Damon J Wischik, John M D Storey, Charles R Harrington
 Following our discovery of a fragment from the repeat domain of tau protein as a structural constituent of the PHF-core in Alzheimer's disease (AD), we developed an assay that captured several key features of the aggregation process. Tau-tau binding through the core tau fragment could be blocked by the same diaminophenothiazines found to dissolve proteolytically stable PHFs isolated from AD brain. We found that the PHF-core tau fragment is inherently capable of auto-catalytic self-propagation in vitro, or "prion-like processing", that has now been demonstrated for several neurodegenerative disorders...
December 8, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29224583/nutrients-for-neurocognition-in-health-and-disease-measures-methodologies-and-mechanisms
#5
Andrew Scholey
Effective pharmaceutical treatments for age-related cognitive decline have proved elusive. There is, however, compelling evidence that nutritional status and supplementation could play crucial roles in modifying the expression of cognitive change through the lifespan. Subjective memory impairment and mild cognitive impairment can be harbingers of dementia but this is by no means inevitable. Neurocognitive change is influenced by a variety of processes, many of which are involved in other aspects of systemic health, including cardiovascular function...
December 11, 2017: Proceedings of the Nutrition Society
https://www.readbyqxmd.com/read/29224502/brentuximab-vedotin-with-chemotherapy-for-stage-iii-or-iv-hodgkin-s-lymphoma
#6
Joseph M Connors, Wojciech Jurczak, David J Straus, Stephen M Ansell, Won S Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J Savage, Nancy L Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier L Zinzani, David Cunningham, Andras Rosta, Neil C Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina A Jolin, Dirk Huebner, John Radford
Background Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee...
December 10, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29223745/buparlisib-plus-fulvestrant-in-postmenopausal-women-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-progressing-on-or-after-mtor-inhibition-belle-3-a-randomised-double-blind-placebo-controlled-phase-3-trial
#7
Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per E Lønning, Wolfgang Janni, Ruth O'Regan, Marie-Ange Mouret-Reynier, Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, Vivianne C G Tjan-Heijnen, Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila Sellami, Thomas Bachelot
BACKGROUND: Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth and proliferation but elicit AKT phosphorylation via a feedback activation pathway, potentially leading to resistance to mTOR inhibitors. We evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced breast cancer who were pretreated with endocrine therapy and mTOR inhibitors...
December 6, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29222605/the-endocannabinoid-system-in-cardiovascular-function-novel-insights-and-clinical-implications
#8
REVIEW
Salvador Sierra, Natasha Luquin, Judith Navarro-Otano
RATIONALE: Cardiovascular disease is now recognized as the number one cause of death in the world, and the size of the population at risk continues to increase rapidly. The dysregulation of the endocannabinoid (eCB) system plays a central role in a wide variety of conditions including cardiovascular disorders. Cannabinoid receptors, their endogenous ligands, as well as enzymes conferring their synthesis and degradation, exhibit overlapping distributions in the cardiovascular system. Furthermore, the pharmacological manipulation of the eCB system has effects on blood pressure, cardiac contractility, and endothelial vasomotor control...
December 8, 2017: Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society
https://www.readbyqxmd.com/read/29221659/cardiovascular-outcomes-with-glucagon-like-peptide-1-receptor-agonists-in-patients-with-type-2-diabetes-a-meta-analysis
#9
M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular efficacy were varied. We aimed to examine overall cardiovascular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide. METHODS: In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke...
December 5, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29219171/benzodiazepines-for-psychosis-induced-aggression-or-agitation
#10
REVIEW
Hadar Zaman, Stephanie J Sampson, Alison Ls Beck, Tarang Sharma, Fiona J Clay, Styliani Spyridi, Sai Zhao, Donna Gillies
BACKGROUND: Acute psychotic illness, especially when associated with agitated or violent behaviour, can require urgent pharmacological tranquillisation or sedation. In several countries, clinicians often use benzodiazepines (either alone or in combination with antipsychotics) for this outcome. OBJECTIVES: To examine whether benzodiazepines, alone or in combination with other pharmacological agents, is an effective treatment for psychosis-induced aggression or agitation when compared with placebo, other pharmacological agents (alone or in combination) or non-pharmacological approaches...
December 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29214563/rare-diseases-joining-mainstream-research-and-treatment-based-on-reliable-epidemiological-data
#11
Stephen C Groft, Manuel Posada de la Paz
Despite growing acceptance of patient registries and natural history studies to provide useful information, the rare disease community suffers from the absence of reliable epidemiological data on the prevalence and incidence of most rare diseases in national and global populations. Likewise, the patients and health care providers lack adequate information on the pathophysiology of rare diseases and expected outcomes of these disorders. The rare diseases community includes all of the stakeholders involved in the research and development and dissemination of products and information for the diagnosis, prevention or treatment of rare diseases or conditions...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29208616/measuring-clinical-trial-transparency-an-empirical-analysis-of-newly-approved-drugs-and-large-pharmaceutical-companies
#12
Jennifer E Miller, Marc Wilenzick, Nolan Ritcey, Joseph S Ross, Michelle M Mello
OBJECTIVES: To define a series of clinical trial transparency measures and apply them to large pharmaceutical and biotechnology companies and their 2014 FDA-approved drugs. DESIGN: Cross-sectional descriptive analysis of all clinical trials supporting 2014 Food and Drugs Administration (FDA)-approved new drug applications (NDAs) for novel drugs sponsored by large companies. DATA SOURCES: Data from over 45 sources, including Drugs@FDA.gov, ClinicalTrials...
December 5, 2017: BMJ Open
https://www.readbyqxmd.com/read/29202708/erdo-a-framework-to-select-an-appropriate-randomization-procedure-for-clinical-trials
#13
Ralf-Dieter Hilgers, Diane Uschner, William F Rosenberger, Nicole Heussen
BACKGROUND: Randomization is considered to be a key feature to protect against bias in randomized clinical trials. Randomization induces comparability with respect to known and unknown covariates, mitigates selection bias, and provides a basis for inference. Although various randomization procedures have been proposed, no single procedure performs uniformly best. In the design phase of a clinical trial, the scientist has to decide which randomization procedure to use, taking into account the practical setting of the trial with respect to the potential of bias...
December 4, 2017: BMC Medical Research Methodology
https://www.readbyqxmd.com/read/29200882/early-intervention-in-the-management-of-pulmonary-arterial-hypertension-clinical-and-economic-outcomes
#14
REVIEW
Charles D Burger, Mohamedanwar Ghandour, Divya Padmanabhan Menon, Haytham Helmi, Raymond L Benza
Pulmonary arterial hypertension (PAH) has a high morbidity rate and is fatal if left untreated. Increasing evidence supports early intervention, possibly with initial combination therapy. PAH-specific pharmaceuticals, however, are expensive and may have serious adverse effects, particularly when used in combination. The currently dynamic health care economy reinforces the need for a review of early intervention from both outcomes and economic perspectives. We aimed to review the clinical and economic impact of PAH therapy, particularly examining drug cost, hospitalization burden, and health care economics impact, and the effect of early intervention on clinical outcomes...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29199000/research-needs-to-understand-self-management-in-men-with-luts-a-review-and-summary-of-an-niddk-workshop
#15
EDITORIAL
Jenna M Norton, Tamara G Bavendam, William Elwood, Steven J Jacobsen, Steven A Kaplan, John W Kusek, Yining Xie, Robert A Star, Ziya Kirkali
Lower urinary tract symptoms (LUTS) are common in men and impose significant economic, health and quality of life burdens. Despite an expanding view of LUTS etiology and challenges with medical and surgical treatments, LUTS research has continued to focus primarily on surgical or pharmaceutical treatment of urinary tract dysfunction, with little attention to behavioral, cognitive, or social factors. Further, self-management research is relatively underdeveloped in urology, despite its potential to support behavioral, pharmacologic, and surgical treatments for LUTS...
November 30, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29197738/efficacy-and-safety-of-levomilnacipran-vilazodone-and-vortioxetine-compared-with-other-second-generation-antidepressants-for-major-depressive-disorder-in-adults-a-systematic-review-and-network-meta-analysis
#16
REVIEW
Gernot Wagner, Marie-Therese Schultes, Viktoria Titscher, Birgit Teufer, Irma Klerings, Gerald Gartlehner
BACKGROUND: Second-generation antidepressants dominate the medical management of major depressive disorder (MDD). Levomilnacipran, vilazodone and vortioxetine are the latest therapeutic options approved for the treatment of MDD. This systematic review aims to compare the benefits and harms of vilazodone, levomilnacipran, and vortioxetine with one another and other second-generation antidepressants. METHODS: We searched electronic databases up to September 2017 and reviewed reference lists and pharmaceutical dossiers to detect published and unpublished studies...
November 16, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29197429/the-economic-contribution-of-industry-sponsored-pharmaceutical-clinical-trials
#17
Dat T Tran, Ilke Akpinar, Richard Fedorak, Egon Jonsson, John Mackey, Lawrence Richer, Philip Jacobs
In pharmaceutical clinical trials, industrial sponsors pay for study drugs and related healthcare services. We conducted a study to determine industry's economic contribution of these trials to the Alberta healthcare system.  Methods: We used data from two trial centers for cancer and non-cancer trials at the University of Alberta. For each trial (cancer, non-cancer), we calculated the cost of drugs provided by the sponsors using the market price, the cost of clinical services, and the cost of administrative services that they paid...
2017: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29197071/peroxisome-proliferator-activated-receptor-gamma-agonists-for-preventing-recurrent-stroke-and-other-vascular-events-in-people-with-stroke-or-transient-ischaemic-attack
#18
REVIEW
Jia Liu, Lu-Ning Wang
BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists are insulin-sensitising drugs used for the treatment of insulin resistance. In addition to lowering glucose in diabetes, these drugs may also protect against hyperlipidaemia and arteriosclerosis, which are risk factors for stroke. This is an update of a review first published in January 2014 and subsequently updated in October 2015. OBJECTIVES: To assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular events for people with stroke or transient ischaemic attack (TIA)...
December 2, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29192424/interventions-for-old-world-cutaneous-leishmaniasis
#19
REVIEW
Julio Heras-Mosteiro, Begoña Monge-Maillo, Mariona Pinart, Patricia Lopez Pereira, Ludovic Reveiz, Emely Garcia-Carrasco, Pedro Campuzano Cuadrado, Ana Royuela, Irene Mendez Roman, Rogelio López-Vélez
BACKGROUND: Cutaneous leishmaniasis, caused by a parasitic infection, is considered one of the most serious skin diseases in many low- and middle-income countries. Old World cutaneous leishmaniasis (OWCL) is caused by species found in Africa, Asia, the Middle East, the Mediterranean, and India. The most commonly prescribed treatments are antimonials, but other drugs have been used with varying success. As OWCL tends to heal spontaneously, it is necessary to justify the use of systemic and topical treatments...
December 1, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29188843/effect-of-suberoylanilide-hydroxamic-acid-saha-on-breast-cancer-cells-within-a-tumor-stroma-microfluidic-model
#20
N Peela, E S Barrientos, D Truong, G Mouneimne, M Nikkhah
Metastatic cancer is regarded as one of the largest contributors to disease-related deaths worldwide. Poor patient prognosis and treatment outcome is tied to the lack of efficacious anti-cancer therapies, which is due in part to the lack of physiologically relevant in vitro screening systems that can mimic the native tumor microenvironment. Conventional drug-screening platforms, which are often used in the pharmaceutical industry, are either two-dimensional (2D) assays or three-dimensional (3D) hydrogel-based matrices that lack precise control over cell distribution, matrix architecture, and organization...
November 30, 2017: Integrative Biology: Quantitative Biosciences From Nano to Macro
keyword
keyword
93344
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"